UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Augmenting human gamma delta lymphocytes for cancer therapy with chimeric antigen receptors

Ferry, Gabrielle M; Anderson, John; (2022) Augmenting human gamma delta lymphocytes for cancer therapy with chimeric antigen receptors. Exploration of Immunology , 2022 (2) pp. 168-179. 10.37349/ei.2022.00042. Green open access

[thumbnail of Anderson_100342.pdf]
Preview
PDF
Anderson_100342.pdf - Published Version

Download (2MB) | Preview

Abstract

Gamma delta lymphocytes (γδ T) sit at the interface between innate and adaptive immunity. They have the capacity to recognize cancer cells by interaction of their surface receptors with an array of cancer cell surface target antigens. Interactions include the binding of γδ T cell receptors, the ligands for which are diverse and do not involve classical major histocompatibility complex (MHC) molecules. Moreover, a variety of natural killer-like and fragment crystallizable gamma (Fcγ) receptors confer additional cancer reactivity. Given this innate capacity to recognize and kill cancer cells, there appears less rationale for redirecting specific to cancer cell surface antigens through chimeric antigen receptor (CAR) expression. Several groups have however reported research findings that expression of CARs in γδ T cells can confer additional specificity or functionality. Though limited in number, these studies collectively identify the potential of CAR-T engineering to augment and fine tune anti-cancer responses. Together with the lack of graft versus host disease induced by allogeneic γδ T cells, these insights should encourage researchers to explore additional γδ T-CAR refinements for the development of off-the-shelf anti-cancer cell therapies.

Type: Article
Title: Augmenting human gamma delta lymphocytes for cancer therapy with chimeric antigen receptors
Open access status: An open access version is available from UCL Discovery
DOI: 10.37349/ei.2022.00042
Publisher version: https://doi.org/10.37349/ei.2022.00042
Language: English
Additional information: © The Author(s) 2022. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Chimeric antigen receptor, gamma delta lymphocytes, adoptive cancer immunotherapy
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
URI: https://discovery.ucl.ac.uk/id/eprint/10146006
Downloads since deposit
99Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item